It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Understanding the trajectory, duration, and determinants of antibody responses after SARS-CoV-2 infection can inform subsequent protection and risk of reinfection, however large-scale representative studies are limited. Here we estimated antibody response after SARS-CoV-2 infection in the general population using representative data from 7,256 United Kingdom COVID-19 infection survey participants who had positive swab SARS-CoV-2 PCR tests from 26-April-2020 to 14-June-2021. A latent class model classified 24% of participants as ‘non-responders’ not developing anti-spike antibodies, who were older, had higher SARS-CoV-2 cycle threshold values during infection (i.e. lower viral burden), and less frequently reported any symptoms. Among those who seroconverted, using Bayesian linear mixed models, the estimated anti-spike IgG peak level was 7.3-fold higher than the level previously associated with 50% protection against reinfection, with higher peak levels in older participants and those of non-white ethnicity. The estimated anti-spike IgG half-life was 184 days, being longer in females and those of white ethnicity. We estimated antibody levels associated with protection against reinfection likely last 1.5-2 years on average, with levels associated with protection from severe infection present for several years. These estimates could inform planning for vaccination booster strategies.
Most people who are infected with SARS-CoV-2 seroconvert within a few weeks, but the determinants and duration of the antibody response are not known. Here, the authors characterise these features of the immune response using data from a large representative community sample of the UK population.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Big Data Institute, Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Department of Infectious Diseases and Microbiology, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492)
3 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Department of Infectious Diseases and Microbiology, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492); The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, The National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 Office for National Statistics, Newport, UK (GRID:grid.426100.1) (ISNI:0000 0001 2157 6840)
5 University of Oxford, Office of the Regius Professor of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
6 Public Health England, Health Improvement Directorate, London, UK (GRID:grid.271308.f) (ISNI:0000 0004 5909 016X)
7 Wellcome Trust, London, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672)
8 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, The National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
9 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
10 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
11 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Big Data Institute, Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Health Economics Research Centre, Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
12 University of Oxford, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Big Data Institute, Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); UCL, MRC Clinical Trials Unit at UCL, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
13 University of Oxford, Big Data Institute, Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Department of Infectious Diseases and Microbiology, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492); The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, The National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
14 Oxford University Hospitals NHS Foundation Trust, Oxford, UK (GRID:grid.410556.3) (ISNI:0000 0001 0440 1440)
15 University of Manchester, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
16 IQVIA, London, UK (GRID:grid.482783.2)
17 National Biocentre, Milton Keynes, UK (GRID:grid.482783.2)
18 Glasgow Lighthouse Laboratory, London, UK (GRID:grid.482783.2)
19 Department of Health and Social Care, London, UK (GRID:grid.57981.32)
20 Welsh Government, Cardiff, UK (GRID:grid.422594.c) (ISNI:0000 0004 1787 8223)
21 Scottish Government, Edinburgh, UK (GRID:grid.421126.2) (ISNI:0000 0001 0698 0044)
22 Public Health Scotland, Edinburgh, UK (GRID:grid.508718.3)